Sampson, J., Achrol, A. S., Aghi, M. K., Bankiewicz, K., Bexon, M., Brem, S., … Butowski, N. (2020). MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. European Journal of Cancer, 138, S6. https://doi.org/10.1016/S0959-8049(20)31084-4

Sampson, J., A. S. Achrol, M. K. Aghi, K. Bankiewicz, M. Bexon, S. Brem, A. Brenner, et al. “MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit.” European Journal of Cancer 138 (October 1, 2020): S6. https://doi.org/10.1016/S0959-8049(20)31084-4.

Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Bexon M, Brem S, et al. MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. European Journal of Cancer. 2020 Oct 1;138:S6.

Sampson, J., et al. “MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit.” European Journal of Cancer, vol. 138, Oct. 2020, p. S6. Scopus, doi:10.1016/S0959-8049(20)31084-4.

Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner A, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Merchant F, Merchant N, Randazzo D, Vogelbaum M, Vrionis F, Zabek M, Butowski N. MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. European Journal of Cancer. 2020 Oct 1;138:S6.